Troriluzole

Summary

Troriluzole (CHEMBL4297586) is a phase-3 clinical-stage protein (ATC N07XX23); indicated across 5 conditions including obsessive-compulsive disorder and generalized anxiety disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• ATC class: N07XX23
• Indications: 5 conditions
• Clinical trials: 12
• Chemistry: 419.4 Da · C15H16F3N5O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297586
Name	Troriluzole
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	121488186
ATC	N07XX23
Molecular formula	C15H16F3N5O4S
Molecular weight	419.4
InChIKey	YBZSGIWIPOUSHY-UHFFFAOYSA-N

SMILES: CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN

IUPAC name: 2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide

Also known as: BHV-4157a, Trigriluzole, Troriluzole, TRORILUZOLE

Parent form; salt/anhydrous children: CHEMBL4297673

Patent coverage: 74 distinct patent families (191 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 134 (70%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obsessive-compulsive disorder	3	MONDO:0008114	EFO:0004242
generalized anxiety disorder	3	MONDO:0001942	EFO:1001892
metastatic melanoma	2	MONDO:0005191	EFO:0002617
glioblastoma	2	MONDO:0018177	EFO:0000519
Alzheimer disease	2	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2/PHASE3	3
PHASE2	2
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03701399	PHASE3	ACTIVE_NOT_RECRUITING	Troriluzole in Adult Participants With Spinocerebellar Ataxia
NCT03970447	PHASE2/PHASE3	RECRUITING	A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT02960893	PHASE2/PHASE3	COMPLETED	Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
NCT03299166	PHASE2/PHASE3	COMPLETED	Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
NCT03829241	PHASE3	COMPLETED	Randomized Trial of Adult Participants With Generalized Anxiety Disorder
NCT04641143	PHASE3	COMPLETED	Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04693351	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder
NCT04708834	PHASE3	TERMINATED	Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
NCT03605667	PHASE2	COMPLETED	Study of BHV-4157 in Alzheimer’s Disease
NCT04899921	PHASE2	TERMINATED	Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
NCT06552260	EARLY_PHASE1	RECRUITING	A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
NCT06034886	Not specified	AVAILABLE	Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).